Volume 2 Supplement 3

Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)

Open Access

Preclinical assessment of a novel small molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1)

  • Gregory Driessens1,
  • Stefano Crosignani1,
  • Michel Detheux1,
  • Benoît Van den Eynde2 and
  • Sandra Cauwenberghs1
Journal for ImmunoTherapy of Cancer20142(Suppl 3):P195

DOI: 10.1186/2051-1426-2-S3-P195

Published: 6 November 2014

Introduction

iTeos leverages the science of the LICR to target the metabolism of the tumor microenvironment and develops small-molecule inhibitors. Tryptophan catabolism can suppress the anti-tumor immune response through expression of the rate-limiting enzyme IDO1. Local tryptophan reduction and metabolite production by the kynurenine pathway are associated with anergy/apoptosis of tumor-infiltrating lymphocytes. Two IDO1 inhibitors (Incyte INCB24360/NewLink NLG919) are currently tested in clinical trials for treatment of relapsed/refractory solid tumors but exhibit therapeutic limitations.

Methods/results

A primary HTS (176,000 compounds) led to the discovery of several confirmed hits. Medicinal chemistry optimization resulted in an original lead with nM potency in a relevant human blood assay, comparable to Incyte IDO1i (IC50 890 ± 220 nM [iTeos IDO1i] versus 970 ± 100 nM [Incyte IDO1i] [N = 3 donors; Kyn ELISA]). For rodents & monkey, iTeos compound showed low clearance (9.9&1.9 mL/min/kg respectively), moderate-to-low protein binding (48&28%Fu respectively), a short half-life in rodents but long in monkey (1.1&12 h respectively), good oral availability (>75%), and no inhibition on five CYP450 isoforms). Good predictive values for human PK were obtained through allometric scaling. Quantification of the tryptophan metabolite kynurenine showed a significant decrease in mouse plasma after oral administration of the IDO1i in a dose response setting (45.3 ± 2.4 [iTeos IDO1i] and 48.1% ± 3.0 [Incyte IDO1i]; 2 h per os at 100 mg/kg compared to vehicle; N = 5 independent experiments). In a time-course experiment, inhibition of kynurenine production lasted 8 h (iTeos IDO1i) compared to 16 h (Incyte IDO1i), consistent with their respective rodent half-life. A comparable PD effect was observed in mouse tumor lysates. Monkey PD is ongoing. Preliminary data obtained with the Pan02 mouse tumor model showed significant survival benefit of the iTeos IDO1i in stand-alone and in combination with anti-CTLA4 treatment compared to vehicle or anti-CTLA4 in stand-alone respectively. 15 different human cancer types (60 samples each) were analyzed for IDO1 protein expression and allowed identification of several tumors with high expression.

Conclusions

iTeos' drug discovery efforts have delivered a selective IDO1 small-molecule inhibitor with novel scaffold suitable for in vitro/in vivo validation and with good predictive human PK (low clearance(<10% QH), long half-life(>20 h), high oral bioavailability).

Authors’ Affiliations

(1)
iTeos Therapeutics
(2)
Ludwig Institute for Cancer Research (LICR, Brussels Branch) and de Duve Institute, Université catholique de Louvain (UCL)

Copyright

© Driessens et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement